This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D66 (hereditary factor VIII deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | CRM-positive hemophilia A, dysfunctional-type hemophilia A, cross-reacting material-positive hemophilia, Factor VIII:C deficiency with normal antigen, Dysfunctional factor VIII deficiency, Hemophilia A CRM+, hemophilia A functional-defect variant |
| C. Adult onset | Likelihood of first presentation in adulthood: considerable — functional-defect hemophilia A (CRM-positive) mostly shows a mild to moderate phenotype with rare spontaneous bleeding, and symptoms often do not surface without a trigger such as surgery, tooth extraction or trauma, so adult cases first diagnosed after age 18 are not uncommon; when FVIII:C results are in the borderline range, it is sometimes discovered incidentally in adulthood from a prolonged APTT on a routine health checkup. |
| 1. History | After the 1952 classification of hemophilia A and B, recognition of variants with the same phenotype but different mechanisms → introduction of the CRM concept in the 1960s–70s (immunological measurement of FVIII antigen) → 1971, Zimmermann established the FVIII antigen assay → molecular-level definition in the 1980s–90s → standardization of assays and renewed attention to clinical importance since the 2000s. |
| 2. Causes | Due to missense mutations in the F8 gene (Xq28), FVIII protein is produced at normal or near-normal levels but is functionally defective. Null variants such as inversions and large deletions cause CRM−, so they are excluded as CRM+ causes. Missense variants in the A2 domain, A1 domain, C2 domain and others are the main causes. |
| 3. Genetics | X-linked recessive inheritance. F8 gene (Xq28, 26 exons). Missense mutations selectively affect specific domain functions (FIXa binding, FX activation, vWF binding, regulation of A2 subunit dissociation after activation). An FVIII:Ag/FVIII:C ratio >2 confirms the protein presence-function discordance. Accounts for about 5% of all hemophilia A. |
| 4. General epidemiology | About 5% of the overall prevalence of hemophilia A (1 in 5,000–10,000 male births) is estimated to be the CRM+ functional-defect type. The absolute number is around 20,000 worldwide. Because most have a mild to moderate phenotype, diagnosis is often delayed. No ethnic or racial differences. |
| 5. Pathophysiology | FVIII protein is produced but has defects in functions such as FIXa cofactor function, A2 subunit stability, vWF binding and C2 membrane binding → reduced efficiency of the FX-activating tenase complex → reduced thrombin generation → bleeding tendency. A2 domain missense variants (about 40%): increased A2 subunit dissociation rate → premature inactivation of FVIIIa. |
| 6. Symptoms | Mostly mild to moderate phenotype. The main symptom is excessive or prolonged bleeding after trauma, surgery or tooth extraction rather than spontaneous bleeding. Rarely, spontaneous hemarthrosis is possible if moderate. Tendency to nosebleeds, gum bleeding and bruising. Bleeding symptoms are also possible in female carriers (Lyon effect). |
| 7. Signs | Isolated APTT prolongation (normal PT, TT and platelets). Reduced FVIII:C (one-stage or chromogenic substrate assay). Normal or mildly reduced FVIII:Ag. FVIII:Ag/FVIII:C ratio >2. Measurement discrepancy between the one-stage and chromogenic substrate assays — in some variants the one-stage assay yields higher values than the chromogenic assay. Inhibitor incidence tends to be lower than in the standard type. |
| 8. Screening | No special screening of the general population. When APTT prolongation is found, FVIII:C is measured. Newborns with a family history: cord blood FVIII activity measurement. Identification of female carriers: F8 gene analysis. When CRM+ is suspected, additional FVIII:Ag measurement and both assay methods (one-stage·chromogenic) in parallel. Prenatal diagnosis (chorionic villus sampling or amniocentesis) and PGT are possible. |
| 9. Diagnosis | ① Confirm APTT prolongation → ② measure FVIII:C (both one-stage and chromogenic substrate assays) → ③ measure FVIII:Ag (immunological method) → ④ calculate the Ag/C ratio (>2.0: suggests CRM+) → ⑤ confirm an F8 gene missense mutation (NGS or Sanger). Discrepancy between assays is a pathognomonic finding of CRM+ functional-defect variants. Inhibitors: Bethesda assay. |
| 10. Treatment | Follows general hemophilia A. Mild: use after checking the response to DDAVP (desmopressin). Moderate to severe: FVIII concentrates (plasma-derived or recombinant) as prophylaxis or on-demand. Emicizumab (subcutaneous injection). Chromogenic assay values may be more accurate for setting treatment targets and monitoring. When inhibitors develop, bypassing therapy or ITI. |
| 11. Prognosis | Mostly mild to moderate phenotype, with normal life expectancy given appropriate treatment. Inhibitor incidence is lower than in null-variant types (however, with certain variants such as R593C, the risk increases when HLA-DRB1*1101 positive). Preventing misdiagnosis and incorrect treatment targets due to assay discrepancy is the key to prognostic management. |
| 12. Prevention | Genetic testing and genetic counseling. Prenatal diagnosis and preimplantation genetic testing (PGT) for carrier women. DDAVP response test in advance (when planning surgery). Preventing diagnostic errors by performing assays in parallel. Establishing an FVIII replacement plan before situations with bleeding risk. |
| 13. References | Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997 … and 9 other articles |
After hemophilia A (hereditary factor VIII deficiency) was clearly defined in 1952, the recognition that subtypes with different molecular mechanisms exist within the same clinical syndrome gradually took shape as immunological techniques developed. In the late 1950s and early 1960s, researchers began to observe that some patients with hemophilia A with reduced FVIII activity (FVIII:C) had near-normal levels of FVIII protein antigen (FVIII:Ag) that reacted with anti-FVIII antiserum. This phenomenon meant that a nonfunctional but immunologically recognizable protein was present, and it was named with the concept of 'cross-reacting material (CRM)'.
The research that contributed decisively to establishing the CRM concept was the rocket immunoelectrophoresis (Laurell immunoelectrophoresis) method using anti-FVIII antiserum published by Zimmermann et al. in 1971. They systematically demonstrated that FVIII antigen was measured at normal or near-normal levels in the serum of some patients with hemophilia A, and on this basis a classification system was proposed dividing hemophilia A into three categories: CRM− (antigen absent), CRM reduced (CRMr) and CRM+ (antigen present, function deficient). At the time, an estimate was given that CRM+ accounts for about 5–10% of all hemophilia A, and this figure was largely confirmed by later molecular genetic studies.
With the cloning of the F8 gene in the 1980s (1984), the molecular basis of CRM+ hemophilia A began to be revealed. Studies demonstrated that the CRM+ phenotype is caused exclusively by missense mutations that produce the protein but alter the structure of specific functional regions, rather than by variants that block protein synthesis itself, such as large deletions or intron inversions. In particular, research by Fay, Pipe, Kaufman and others in the 1990s made clear that certain missense variants in the A2 domain increase the dissociation rate of the A2 subunit in activated FVIII (FVIIIa), causing premature inactivation.
In the late 1990s and early 2000s, clinically important missense variants were systematically reported. Variants such as Arg593Cys (R593C), Arg2150His (R2150H), Arg1781His (R1781His) and Ala2201Pro (A2201P) were identified as causing the CRM+ phenotype, and among them R593C drew clinical attention when research by Gouw et al. (2012) revealed that the risk of inhibitor development rises in patients carrying a specific HLA-DRB1*1101 haplotype. This was also the period when reports began to appear that the measurement discrepancy between the one-stage clotting assay and the chromogenic substrate assay (one-stage vs. chromogenic discrepancy) appears reproducibly in some CRM+ variants.
Since the 2010s, with the spread of next-generation sequencing (NGS), CRM+-causing missense variants have been discovered and classified on a large scale, and hundreds or more functional-defect variants have been registered in international databases (CHAMP, HAMSTeRS). In addition, as chromogenic substrate assays and immunological FVIII:Ag measurement were included in standard diagnostic algorithms, it was reaffirmed that the CRM+ functional-defect type is not merely an academic classification but a clinically practical one for treatment monitoring and prediction of inhibitor risk. Entering the era of emicizumab, the problem of discrepancy between FVIII:C assays has also emerged as an important topic of discussion in treatment monitoring methodology.
Factor VIII deficiency with functional defect is caused by missense mutations in the F8 gene located on the long arm of the X chromosome (Xq28). The key feature of this type is that the FVIII protein is synthesized and secreted in near-normal amounts but its function as a coagulation cofactor is markedly impaired. The functional-defect type is clearly distinguished from CRM-negative (CRM−) variants, in which FVIII protein is structurally not produced at all or produced only in trace amounts.
In terms of the type of causative variant, the functional-defect type (CRM+) is caused exclusively by missense mutations; large deletions, frameshifts due to small deletions or insertions, splice-site mutations, premature stop codon variants (nonsense mutations), and rearrangement variants such as intron 22 inversion or intron 1 inversion do not cause the CRM+ phenotype. This is because null variants block protein synthesis itself or produce extremely unstable peptides. Among missense variants, only those located in specific functional domains (A1, A2, A3, C1, C2) of the FVIII protein cause the CRM+ phenotype, while variants that act lethally on protein folding or on the assembly process within the endoplasmic reticulum correspond to CRM− or CRM reduced (CRMr).
The best-studied CRM+-causing missense variants are concentrated in the A2 domain. Activated FVIII (FVIIIa) is a heterotrimer in which the three subunits A1, A2 and A3 are noncovalently linked by metal ions, and the physiological inactivation of FVIIIa occurs through dissociation of the A2 subunit from the complex. When a missense variant in the A2 domain abnormally accelerates the dissociation rate of the A2 subunit, FVIIIa is prematurely inactivated and the efficiency of FX activation is reduced. Representative variants with this mechanism include Arg593Cys (R593C), Arg545His and Glu665Val.
The second major group consists of variants located at the FIXa binding site or FX activation site; variants in the acidic region of the A2 domain (residues 558–565) or the A1/A2 boundary interfere with protein-protein interaction with FIXa and hinder tenase complex assembly. The third group is C2 domain variants, which impair binding to von Willebrand factor (vWF) or phospholipid membranes, shortening the plasma half-life of FVIII or reducing the efficiency of complex assembly on platelet membranes. Some C2 variants show the typical CRM+ pattern of normal FVIII:Ag with reduced FVIII:C.
The mode of inheritance is X-linked recessive, the same as standard hemophilia A. When the mother is a carrier of the missense variant, 50% of sons are affected and 50% of daughters become carriers. Cases also arise from de novo mutations without a family history, but the rate of de novo occurrence of CRM+ variants is known to be relatively low compared with null variants. Female carriers may have low measured FVIII:C due to lyonization (X inactivation), and some show bleeding symptoms.
The F8 gene is located on the long arm of the X chromosome (Xq28), with a total length of about 186 kb, and consists of 26 exons. This gene encodes a protein precursor of 2,332 amino acids, and after cleavage of the signal peptide the mature protein has a multidomain structure of A1-A2-B-A3-C1-C2. The B domain is not directly essential for coagulant function but contributes to protein secretion and stability. Missense variants causing the functional-defect type (CRM+) are concentrated at functionally important residues within these domains.
The structure-function relationship of the A2 domain is key to understanding the molecular characteristics of functional-defect missense variants. The A2 domain is linked to the A1 domain via divalent copper ions (Cu²⁺), and after activation the A2 subunit in FVIIIa sits noncovalently on the A1·A3·C1·C2 bilayer. Arg593 (human mature protein numbering) is a key residue involved in electrostatic interactions at the A2-A3 interface; the Arg593Cys (R593C) substitution weakens this interaction, increasing the spontaneous dissociation rate (koff) of the A2 subunit 2–5-fold and consequently shortening the FVIIIa half-life, causing a functional defect. This variant is one of the most frequently reported single variants among all CRM+ hemophilia A.
The international databases HAMSTeRS (Haemophilia A Mutation, Structure, Test and Resource Site) and CHAMP (CDC Hemophilia A Mutation Project) register hundreds of missense variants causing CRM+ or CRM reduced types. In terms of their distribution, the A2 domain (based on exon 14) accounts for the largest share, and variants in the A1 domain (acidic residues related to FIXa binding, etc.), A3 domain (C-terminal portion for FIXa binding) and C2 domain (vWF and phospholipid binding loops) make up the rest. Missense variants in the B domain generally tend to cause impaired protein secretion rather than functional defects and have a low association with the CRM+ phenotype.
Another clinically important aspect of the genetic characteristics of the functional-defect type is the association between inhibitor risk and variant type. CRM+ patients overall have a lower inhibitor incidence than CRM− patients (large deletions, inversions, etc.). This is explained by the fact that the immune system of CRM+ patients is exposed to endogenous FVIII protein antigen, so relative immune tolerance is maintained. However, as an exception, the R593C variant was confirmed in a large cohort study by Gouw et al. (2012) to significantly increase the risk of inhibitor development in carriers of the HLA-DRB1*1101 haplotype. This is presumed to be because certain HLA molecules efficiently present peptides derived from R593C variant FVIII, promoting FVIII-specific CD4+ T-cell responses and thereby promoting inhibitor formation.
In terms of genetic counseling, genetic analysis of carrier women in whom the functional-defect type has been confirmed can identify the exact variant type, and prenatal diagnosis (chorionic villus sampling at 11–14 weeks, amniocentesis at 15–20 weeks) or preimplantation genetic testing (PGT) can be performed. Carrier women themselves may also have FVIII:C reduced below the normal range due to the Lyon effect (skewed X inactivation); in such cases, performing both the one-stage and chromogenic substrate assays and measuring FVIII:Ag are useful for accurately assessing carrier status.
Factor VIII deficiency with functional defect (CRM-positive hemophilia A) is a rare subtype that accounts for a portion of all patients with hemophilia A. Hemophilia A as a whole has a prevalence of about 1 in 5,000–10,000 male births, and the CRM+ functional-defect type is estimated at about 5% of these. That is, it is a very rare type, corresponding to about 1 in 250,000–500,000 of all males. Worldwide, about 15,000–20,000 patients are estimated to exist, but the number of patients actually identified may be smaller depending on differences in diagnostic criteria and access to testing.
An important epidemiological feature is that the distribution of clinical severity in patients with CRM+ functional-defect hemophilia A differs from that of CRM− patients. Most CRM− variants (intron 22 inversion, large deletions, etc.) cause a severe phenotype (FVIII:C < 1%), whereas CRM+ missense variants are distributed across mild (FVIII:C 5–40%), moderate (1–5%) or, rarely, severe ranges depending on the residual functional activity of the FVIII protein. Clinical series have reported that mild to moderate cases make up the majority of CRM+ patients, and as a result diagnosis is not uncommonly delayed until adulthood.
The sex distribution is overwhelmingly male, as in standard hemophilia A; female carriers have FVIII:C at about 50% of normal on average, but due to the Lyon effect some carrier women have FVIII:C reduced to a level similar to mild hemophilia A and experience bleeding symptoms. There is no ethnic or geographic specificity, and it occurs in all races worldwide. Regional differences in the frequency of specific variants are sometimes explained by a founder effect, but the overall prevalence of the functional-defect type is known not to differ significantly between ethnic groups.
Epidemiological data in Korea include the Korea Hemophilia Registry (KBDR), but large-scale domestic data that separately classify and count CRM status are still limited. According to findings to date, among Korean patients with hemophilia A who underwent genetic testing, functional-defect missense variants have been reported in about 5% of the total, which is consistent with international statistics. Because the total number of registered patients with hemophilia A in Korea is around 2,100 (as of the 2020s), the functional-defect type is estimated to account for just over 100 people in Korea.
Acquired hemophilia A is an entirely different disease caused by inhibition of FVIII function by autoantibodies, so it must be clearly distinguished from the hereditary functional-defect type. Special Copayment Reduction V009 applies to patients with hereditary hemophilia A (including CRM+), and the copayment for covered care is reduced to 10% for 5 years after registration. Application is made by the medical institution submitting it to the National Health Insurance Service (NHIS) with the relevant test and genetic analysis results attached.
The core of the pathophysiology of factor VIII deficiency with functional defect is that the FVIII protein is synthesized and secreted at normal or near-normal levels but cannot adequately perform its cofactor function within the intrinsic tenase complex of the intrinsic coagulation pathway. To understand this, it is first necessary to look at the functional cycle of normal FVIII.
Under normal conditions, FVIII circulates in plasma in a noncovalent complex with von Willebrand factor (vWF), and this binding protects FVIII from proteolytic degradation and maintains its half-life in the blood. When FVIII is activated (FVIIIa) by thrombin (IIa) or factor X (FXa) at the site of vascular injury, it dissociates from vWF, binds to phospholipids on the activated platelet membrane surface, and there binds activated factor IX (FIXa) to form the intrinsic tenase complex (FIXa·FVIIIa·Ca²⁺·phospholipid). This complex accelerates the enzymatic reaction converting factor X (FX) to its active form (FXa) by about 100,000–1,000,000-fold, and FXa converts prothrombin to thrombin to form a fibrin clot.
In the functional-defect type, this process is impaired by several mechanisms depending on the location of the missense variant. The first and best-studied mechanism is premature inactivation of FVIIIa. Activated FVIIIa is physiologically an unstable heterotrimer in which the A2 subunit is noncovalently bound on the A1·A3-C1-C2 bilayer, and spontaneous dissociation of the A2 subunit is one of the main inactivation mechanisms of FVIIIa. Missense variants in the A2 domain (R593C, R545H, etc.) weaken the electrostatic interaction between the A2 subunit and the A3 domain, increasing koff (the A2 dissociation rate constant) and consequently shortening the effective half-life of FVIIIa within the tenase complex. Research by Fay et al. (Blood, 1999) experimentally demonstrated that R593C variant FVIIIa has an A2 subunit dissociation rate about 3 or more times faster than wild type and markedly reduced FX activation efficiency.
The second mechanism is reduced ability to bind FIXa. The acidic region of the A2 domain (residues 558–565) and some residues of the A3 domain form an interface in direct contact with FIXa, and missense variants at these sites increase FIXa affinity (Km) or decrease the maximum reaction velocity (Vmax), lowering the catalytic efficiency of the tenase complex. The third mechanism is impaired phospholipid or vWF binding. C2 domain variants reduce the binding affinity of FVIII for platelet membrane phospholipids, lowering the efficiency of membrane anchoring of the tenase complex, or in some cases excessive affinity for vWF (poor dissociation) prevents sufficient dissociation from vWF even after activation, interfering with phospholipid binding.
Assay discrepancy is a characteristic laboratory finding that reflects the pathophysiology of the functional-defect type. The one-stage clotting assay is based on the activated partial thromboplastin time (APTT) and measures the degree of clotting correction when patient plasma is mixed with FVIII-deficient substrate plasma. Because this method contains contact activators such as kaolin and phospholipids, the plasma environment differs from that in the body, and especially in some missense variants FVIII activity may be overestimated under the test conditions. In contrast, the chromogenic substrate assay uses purely purified reagents to measure FX activation directly, so in cases where FVIIIa is prematurely inactivated in the body, such as variants that accelerate A2 dissociation, it provides values closer to actual in vivo function. As a result, a discrepancy appears in some CRM+ variants in which the one-stage assay yields higher values than the chromogenic assay.
The clinical symptoms of factor VIII deficiency with functional defect depend largely on the residual level of FVIII function, and most patients show a mild (FVIII:C 5–40%) or moderate (FVIII:C 1–5%) phenotype. Spontaneous intra-articular bleeding and muscle hematomas typically seen in severe hemophilia A (FVIII:C < 1%) are rare in functional-defect patients; instead, a tendency to bleed from external stimuli makes up the main clinical picture.
The most common symptom in patients with the mild phenotype is excessive and prolonged bleeding after surgical procedures, dental extraction or trauma. The typical pattern is failure of hemostasis or repeated rebleeding over hours to days after a simple laceration or minor surgery. Such bleeding is not controlled by local hemostatic measures alone, and the difficulty of achieving hemostasis without FVIII products or DDAVP is a diagnostic clue. A history of bleeding that does not stop for more than a day after tooth extraction, or of repeated rebleeding despite suturing after a minor incision, strongly suggests mild hemophilia A.
In patients with the moderate phenotype, spontaneous bleeding episodes may rarely occur in addition to traumatic bleeding. Soft tissue hematomas, intramuscular bleeding or small-joint hemarthrosis may occur intermittently, accompanied by local pain, swelling and fever. However, the pattern of spontaneous bleeding recurring once or twice a week, as in severe standard hemophilia A, is uncommon. In some moderate patients, a spontaneous bleeding episode is observed only about once every few years.
Mucosal bleeding also occurs relatively often, with reports of persistent or recurrent nosebleeds (epistaxis) that do not stop easily with local pressure and gum bleeding that persists after toothbrushing. Some female carriers have reduced FVIII:C due to the Lyon effect and may experience heavy menstrual bleeding (menorrhagia) or postpartum hemorrhage, which sometimes first reveals their carrier status.
In the neonatal period, excessive bleeding after circumcision, hematomas at blood sampling sites and scalp hematomas may appear as the first symptoms; in the mild phenotype, it is not uncommon for the neonatal period to pass without symptoms and for the diagnosis to be made for the first time after surgery or trauma in adulthood. Intracranial hemorrhage is regarded as the most feared complication in severe hemophilia A, but in the mild to moderate functional-defect type the risk of spontaneous intracranial hemorrhage is low. However, with head trauma the risk of intracranial hemorrhage may be higher than in normal individuals, so caution is needed.
The clinical signs of factor VIII deficiency with functional defect are broadly divided into laboratory findings and physical examination findings. Because most patients show a mild to moderate phenotype, chronic hemophilic arthropathy and muscle fibrosis, which can be seen in severe hemophilia A, are relatively rare in functional-defect patients.
Isolated prolongation of the APTT (activated partial thromboplastin time) is the typical screening finding. PT (prothrombin time), thrombin time (TT), fibrinogen, and platelet count and function are all normal. FVIII:C, measured by the one-stage assay or chromogenic substrate assay, is reduced. The most characteristic laboratory finding in the functional-defect type is measurement discrepancy between the two assays (one-stage vs. chromogenic assay discrepancy); in some variants, the one-stage assay yields significantly higher FVIII:C values than the chromogenic assay. When this discrepancy is clinically meaningful (e.g., >2-fold difference), it is regarded as a pathognomonic sign of the functional-defect type.
FVIII:Ag (FVIII antigen) is measured by immunological methods (enzyme-linked immunosorbent assay, ELISA, or immunoelectrophoresis) and in the functional-defect type is at normal or mildly reduced levels (usually 50% or more of the normal reference value). An FVIII:Ag/FVIII:C ratio above 2.0 strongly suggests the CRM+ functional-defect type. This ratio is used as a key indicator in the diagnostic algorithm for CRM+ patients.
Inhibitor testing is performed by the Bethesda method or the Nijmegen-Bethesda modification, and in the functional-defect type the inhibitor incidence is known to be lower than in patients with null variants, even among previously untreated patients (PUP) who have never received FVIII. However, among patients with the R593C variant, the inhibitor risk exceptionally increases in those who are HLA-DRB1*1101 positive.
In mild to moderate patients in a stable state without acute bleeding episodes, there are usually no specific physical examination findings. When hemarthrosis occurs, swelling, warmth, skin redness and restricted movement of the affected joint are observed, with marked tenderness of the joint space. After recurrent hemarthrosis, synovial thickening, cartilage erosion and joint stiffness progress, and radiological and functional signs of hemophilic arthropathy may appear, but progression to this stage is rare in functional-defect patients.
When a muscle hematoma occurs, swelling, induration and tenderness of the affected muscle are palpable, and an iliopsoas hematoma may be accompanied by groin pain and sensory abnormalities due to femoral nerve compression. Hematomas or residual hematomas from scalp, mucosal or intraoral bleeding may also be observed. On the skin, relatively large ecchymoses tend to develop even after minor trauma, and hematomas at venipuncture sites tend to keep expanding.
Population-based public health screening of the general population for factor VIII deficiency with functional defect is not currently performed. This is because the disease is an X-linked genetic disorder expressed in males, its prevalence is relatively low, and many cases have a mild to moderate phenotype with little immediate threat to life in daily living. Screening is mainly targeted at high-risk groups (family history, suspicious symptoms).
For male newborns born to women who are hemophilia A carriers, FVIII:C measurement on cord blood or venous blood immediately after birth or within the first few days of life is recommended. At this age, FVIII:C in normal newborns is at the same level as the adult normal range, so measurements can be interpreted without separate correction. If invasive procedures in the neonatal period (circumcision, umbilical vessel catheterization, etc.) are planned, preemptive FVIII measurement is essential.
To diagnose the functional-defect type, it is important to perform both the one-stage and chromogenic substrate assays and check whether the two values are discordant. With the one-stage assay alone, FVIII:C may be wrongly measured as near normal in some missense variants, so the diagnosis can be missed. Measuring FVIII:Ag at the same time and calculating the Ag/C ratio allows early assessment of the likelihood of the functional-defect type.
As a rule, female relatives of known patients with hemophilia A should have their carrier status confirmed by molecular genetic testing of the F8 gene. Because functional-defect variants require direct detection of missense variants, exon-by-exon sequencing (Sanger method) or multigene panel testing (NGS) is needed, unlike intron 22·1 inversion analysis. FVIII:C measurement alone may be incomplete for identifying carriers, so genetic testing is recommended as the gold standard.
When isolated APTT prolongation is found on a blood test performed for another reason, the following tests are performed sequentially to screen for FVIII deficiency: ① FVIII:C (one-stage assay) measurement → ② if abnormal, additional FVIII:C (chromogenic substrate assay) → ③ FVIII:Ag measurement → ④ vWF antigen and activity tests (to differentiate von Willebrand disease) → ⑤ F8 gene analysis. In particular, when the APTT is prolonged but one-stage FVIII:C is in the borderline range (30–50%), adding the chromogenic assay and Ag measurement can prevent missed diagnosis of the functional-defect type.
When a carrier woman is pregnant, after determining fetal sex, prenatal genetic diagnosis is possible only for male fetuses through chorionic villus sampling (CVS; 11–14 weeks of gestation) or amniocentesis (15–20 weeks of gestation). Preimplantation genetic testing (PGT) identifies affected embryos through embryo genetic analysis during in vitro fertilization; because the missense variant must be confirmed, the variant information must be known in advance.
Diagnosis of factor VIII deficiency with functional defect follows a stepwise approach, and unlike standard hemophilia A, FVIII:Ag measurement and comparison of the two assays are essential. Overlooking assay discrepancy during the diagnostic process can lead to missed diagnosis or underestimation of severity in patients with the mild phenotype.
APTT, PT, TT, fibrinogen and platelet count are performed. The typical pattern of functional-defect hemophilia A is isolated APTT prolongation with normal PT. The differential diagnosis of isolated APTT prolongation includes hemophilia A, hemophilia B, von Willebrand disease (severe), factor XI (FXI) deficiency, lupus anticoagulant (LA) and heparin. In the APTT mixing test (1:1 mixing of patient plasma + normal plasma), correction suggests factor deficiency and failure to correct suggests an inhibitor (LA, etc.).
Both the one-stage clotting assay (OSA) and the chromogenic substrate assay (CSA) are performed. In the functional-defect type, OSA values may measure significantly higher than CSA values (e.g., OSA 25% vs. CSA 8%), in which case the chromogenic assay is interpreted as closer to actual in vivo function. A ratio of the two values (OSA/CSA > 2) has been proposed as one of the diagnostic criteria for the functional-defect type. Discrepancy in the opposite direction (CSA > OSA) is also not uncommonly reported.
FVIII:Ag is measured by ELISA or immunoelectrophoresis. In the functional-defect type, Ag is normal or mildly reduced (usually 50% or more of the normal reference value), and an FVIII:Ag/FVIII:C (chromogenic) ratio above 2.0 strongly suggests the CRM+ functional-defect type. In CRM− hemophilia A (inversions, large deletions), Ag is also reduced and the ratio is around 1.
In patients with reduced FVIII:C, vWF antigen (vWF:Ag), vWF ristocetin cofactor activity (vWF:RCo) and the vWF-FVIII binding assay (vWF:FVIII binding assay) are performed to differentiate von Willebrand disease (vWD, especially type 2N). In vWD type 2N, vWF:Ag is normal but FVIII binding capacity is reduced, resulting in isolated reduction of FVIII:C; the fact that it is autosomal recessive and therefore expressed in both males and females helps with differentiation.
Next-generation sequencing (NGS) or Sanger sequencing is performed to confirm an F8 gene missense variant. The functional-defect type is negative on MLPA, which detects large deletions or inversions, and on intron 22 inversion PCR, so sequencing of all exons is needed. Variant pathogenicity is determined according to ACMG/AMP criteria by integrating clinical context, functional study data, population frequency and in silico prediction tools. It is important to check for previous reports in international databases (LOVD, ClinVar, HAMSTeRS).
In patients with a history of FVIII concentrate administration, when the treatment response is lower than expected or bleeding control is insufficient, the inhibitor (FVIII inhibitor) is quantified by the Nijmegen-Bethesda method. A titer below 0.6 Bethesda Units (BU)/mL is negative, and 0.6 BU/mL or higher is positive. Inhibitor incidence is generally low in the functional-defect type, but the risk is high with the combination of HLA-DRB1*1101 positivity and the R593C variant, so in this case regular inhibitor monitoring is recommended from the start of initial treatment.
Treatment of factor VIII deficiency with functional defect is carried out within the same framework as the standard treatment principles for hemophilia A, but there are several important special considerations. Most important is to use the chromogenic substrate assay (CSA) for FVIII:C monitoring and, for variants with assay discrepancy, to set CSA-based target values as treatment goals.
Desmopressin (DDAVP; 1-desamino-8-D-arginine vasopressin) promotes the secretion of FVIII and vWF from endothelial cells, transiently raising blood FVIII:C 2–3-fold. In mild functional-defect patients (baseline FVIII:C 5–40%), if a sufficient rise in FVIII:C is achievable, hemostasis with DDAVP alone is possible for minor bleeding or minor surgery. However, the FVIII released into the blood by secretory stimulation carries the same functional-defect variant, so its effect may be limited compared with normal FVIII; therefore, a desmopressin challenge test must be performed in advance in each patient to confirm the magnitude of the FVIII:C rise and the hemostatic effect. DDAVP can be given by intravenous, subcutaneous or intranasal routes, and caution is needed because tachyphylaxis develops with repeated dosing within 48–72 hours.
For patients in whom DDAVP is insufficient or who show a moderate or more severe phenotype, FVIII concentrates are the foundation of treatment. Both plasma-derived (pd) and recombinant (r) FVIII products can be used, divided into standard half-life (SHL) and extended half-life (EHL) products. EHL products (e.g., PEGylated FVIII, Fc-fusion FVIII) can maintain prophylaxis with injections once or twice a week, improving patient adherence. The target FVIII:C during prophylaxis is set from 1% or higher (minimum target) to 3–5% or higher (ideal target) depending on bleeding type and frequency, and levels of 50–100% are maintained around surgery.
In functional-defect patients, FVIII:C monitoring uses both the one-stage and chromogenic assays, but for variants with assay discrepancy the chromogenic value more accurately reflects actual hemostatic capacity, so treatment targets should be set and effects evaluated based on the chromogenic assay. Setting treatment targets based only on one-stage values risks overestimating actual in vivo FVIII function and leaving the patient undertreated.
Emicizumab (brand name: Hemlibra) is a bispecific antibody that binds FIXa and FX simultaneously, mimicking the function of FVIII to replace the intrinsic tenase complex. It is given by subcutaneous injection once weekly, every other week or once monthly. It can be used in patients with functional-defect hemophilia A regardless of inhibitor status, and it is particularly excellent in terms of adherence because of its low injection frequency and long half-life. During emicizumab treatment, standard FVIII:C tests (one-stage or chromogenic) can be subject to interference by emicizumab itself, so a separate method that removes the effect of emicizumab is needed when measuring FVIII:C. The HAVEN 1, 3 and 4 clinical trials confirmed that it markedly reduces major bleeding events.
Fitusiran (brand name: Qfitlia) is an siRNA-based RNAi therapeutic targeting antithrombin (AT) that prevents bleeding by increasing the coagulation tendency of the blood, given by subcutaneous injection once a month. In March 2025, it was approved by the US FDA for routine prophylaxis in patients with hemophilia A and B with or without inhibitors. Because its mechanism is independent of FVIII, it can also be used in functional-defect patients. Because of the risk of thrombosis, caution is needed when it is combined with FVIII products or bypassing agents.
Valoctocogene roxaparvovec (Roctavian) is a one-time intravenous gene therapy using a hepatocyte-targeted AAV5 vector, approved by the FDA in 2022 for adult patients with severe hemophilia A. Cases have been reported in which FVIII:C rose to the normal range within 1–2 years after treatment, reaching a level at which prophylaxis could be stopped. However, large-scale clinical data for functional-defect patients are still limited, and the durability of long-term efficacy and hepatotoxicity issues are being monitored.
The prognosis of factor VIII deficiency with functional defect is generally good, and with early diagnosis and appropriate treatment in the modern medical environment, life expectancy can reach almost the same level as the general population. This is because most patients show a mild to moderate phenotype with a low frequency of spontaneous bleeding, and mild cases often respond to DDAVP, so many bleeding episodes can be managed without intensive factor replacement.
The most important factor affecting prognosis is whether inhibitors develop. When inhibitors develop, the effect of FVIII concentrates is markedly reduced and bypassing agents or immune tolerance induction (ITI) therapy become necessary, greatly increasing the treatment burden and bleeding risk. The overall inhibitor incidence in functional-defect (CRM+) patients tends to be lower than in patients with null variants (large deletions, inversions), but an exceptional increase in risk has been reported with the combination of the R593C variant and HLA-DRB1*1101 positivity. Therefore, in patients with the R593C variant, HLA typing should be considered before starting initial FVIII treatment, and intensive inhibitor monitoring is recommended during the early phase of initial treatment (the first 20–50 exposure days).
Diagnostic delay is a prognostic factor that is particularly problematic in functional-defect patients. When patients with the mild phenotype remain asymptomatic until surgery and are first discovered through excessive bleeding after major surgery or trauma, transfusion, surgical hemostatic procedures and even inappropriate anticoagulant therapy may be given without knowledge of the hemophilia diagnosis. In addition, because of assay discrepancy, when only the one-stage assay is performed, FVIII:C may be measured at a borderline value, leading to errors in which the diagnosis is missed or clinical severity is assessed as lower than it actually is. Such diagnostic errors lead to failure to plan FVIII replacement before surgery or procedures and cause serious bleeding complications.
In the functional-defect type, the long-term prognosis of hemophilic arthropathy is much better than in patients with severe standard hemophilia A. Because the frequency of spontaneous hemarthrosis is low, synovial iron deposition, chronic inflammation and cartilage destruction from recurrent intra-articular bleeding progress much more slowly. When prophylaxis is maintained after early diagnosis, joint function can be preserved close to normal into adulthood. However, in some patients with the moderate phenotype, target joints may develop over a long period.
The introduction of non-factor replacement therapies such as emicizumab and fitusiran, and advances in gene therapy, are expected to further improve the long-term prognosis of hemophilia A as a whole, including functional-defect hemophilia A. In particular, emicizumab markedly reduces bleeding frequency and the injection burden, contributing greatly to improved quality of life (QoL), and gene therapy theoretically offers the possibility of normalizing FVIII:C for a long period with a single dose and achieving complete freedom from bleeding.
Prevention of factor VIII deficiency with functional defect is approached in three stages: primary prevention (preventing disease onset through genetic testing and genetic counseling), secondary prevention (preventing complications through early diagnosis and prophylaxis), and tertiary prevention (preventing long-term complications in affected individuals).
For women in the families of patients with functional-defect hemophilia A (the patient's mother, sisters and daughters), it is recommended to provide genetic testing and genetic counseling to determine carrier status. When a carrier woman plans pregnancy, options for prenatal diagnosis (CVS or amniocentesis) and preimplantation genetic testing (PGT) are discussed in advance through genetic counseling. For functional-defect variants, prenatal diagnosis is possible only if the missense variant information has been confirmed in advance, so it is important to record the variant information accurately and share it with the family when carrier status is confirmed. An ethical approach that respects the patient's autonomy and confidentiality is essential in this process.
After the diagnosis is confirmed, the decision is made whether to perform early prophylaxis (primary prophylaxis). In mild functional-defect patients, spontaneous bleeding is rare, so management is often with on-demand treatment. However, when the phenotype is moderate or more severe or spontaneous bleeding episodes recur, starting prophylaxis is recommended, and emicizumab, with its low subcutaneous injection frequency and high adherence, can also be considered in moderate functional-defect patients. A DDAVP challenge test should be performed in all mild patients, and a plan is made so that patients responsive to DDAVP can use DDAVP preemptively before surgery or tooth extraction.
In functional-defect variants with assay discrepancy, it is important for preventing complications to set preoperative FVIII:C targets based on the chromogenic assay and to monitor FVIII:C during and after surgery with the chromogenic assay. Educating surgeons and anesthesiologists in advance about the patient's functional-defect diagnosis and the assay-specific features, and establishing a system of consultation with a hematologist, prevents surgery-related bleeding incidents.
The goal of tertiary prevention is to prevent complications such as long-term joint damage, inhibitor development and viral infection (in patients using plasma-derived products) in already diagnosed patients. To maintain joint health, regular musculoskeletal assessment (ultrasound, MRI) is combined with rehabilitation exercise therapy, and nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin are in principle avoided because they can worsen bleeding by inhibiting platelet function. To prevent inhibitors, regular prophylaxis is preferred over short-term intensive exposure during initial treatment, and patients with the R593C variant undergo intensive monitoring early in initial treatment. In addition, comprehensive long-term management is provided through registration at a hemophilia treatment center, an individual emergency bleeding plan, family education and links to patient support groups.